Interview: Vivoryon Raises €43m After Alzheimer's Revival
German Biotech Can Fund PQ912 Phase IIb Trials
Executive Summary
New life has been breathed into Alzheimer's research following the reversal of fortunes for Biogen's aducanumab and Vivoryon is benefiting from the upturn in sentiment for the field.
You may also be interested in...
BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies
Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.
AstraZeneca's Evusheld Revenue Stream To Dry Up Soon
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.
Midatech Survival Plan Scuppered By Shareholders
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.